Key result
Administration of reserpine limited the extent of cardiac enlargement in copper-deficient rats, but significantly reduced heart total noradrenaline.
Why the study?
Does reserpine limit cardiac enlargement in rats with copper deficiency?
Does reserpine limit cardiac enlargement in rats with copper deficiency?
In a rat model of copper deficiency, reserpine limits cardiac enlargement independently of noradrenaline concentrations, suggesting a mechanism related to altered cardiac energy status.
Suggests noradrenaline-independent cardioprotection in copper-deficient models; hypothesis-generating and leaves open human translation.
Copper (Cu) deficiency, induced in rats by suckling from Cu-deficient dams and by offering a semisynthetic low-Cu diet from weaning, resulted in cardiac enlargement. This enlargement was not due to accumulation of excess fluid in the heart but was characterized by mitochondrial hypertrophy as demonstrated by electron microscopy and biochemical studies. Administration of reserpine limited the extent of cardiac enlargement; however, heart total noradrenaline (NA), unchanged by Cu deficiency, was significantly reduced by reserpine. It was concluded that cardiac enlargement in Cu deficiency was not directly related to NA concentration. An alteration in cardiac energy status, however, was suggested by reduction in activity of the nonheme iron-dependent enzyme, succinic dehydrogenase.
No takes yet. Share an insight, caveat, or question.
Lawrence et al. (1988) studied Copper deficiency-induced cardiac enlargement. Reserpine was evaluated on Cardiac enlargement and total noradrenaline (NA). Administration of reserpine limited the extent of cardiac enlargement in copper-deficient rats, but significantly reduced heart total noradrenaline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: